Compare Stocks → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ADDXFNASDAQ:ADXSNASDAQ:FWPOTCMKTS:QBIONASDAQ:ZFGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/AADXSAyala Pharmaceuticals$0.64-8.6%$0.74$0.51▼$1.95$6.88M1.6525,718 shs16,416 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/AQBIOQ BioMed$0.00$0.00$0.00▼$0.02$40K1.4913,273 shsN/AZFGNZafgen$7.27+0.8%$18.47$0.62▼$2.76$272.22M0.27360,199 shs442,161 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%ADXSAyala Pharmaceuticals-8.57%+8.47%-25.67%-4.05%-48.80%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%QBIOQ BioMed0.00%0.00%+200.00%-25.00%-97.99%ZFGNZafgen0.00%-15.13%-41.36%+57.93%+65.11%Warning: this could blow your mind (Ad)Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex TherapeuticsN/AN/AN/AN/AADXSAyala Pharmaceuticals2.00HoldN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AADXSAyala Pharmaceuticals$3.24M2.12N/AN/A($0.61) per share-1.05FWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/AQBIOQ BioMed$280K0.16N/AN/A($0.11) per share0.00ZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AADXSAyala PharmaceuticalsN/AN/A0.00∞N/AN/A-2,798.92%-195.41%5/21/2024 (Estimated)FWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/AQBIOQ BioMed-$2.05M-$0.03N/A∞N/AN/AN/AN/A5/26/2024 (Estimated)ZFGNZafgen-$45.41M-$1.07N/A∞N/AN/A-51.34%-34.55%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/AADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDXFAddex TherapeuticsN/AN/AN/AADXSAyala PharmaceuticalsN/A0.530.53FWPForward Pharma A/SN/A18.43N/AQBIOQ BioMedN/AN/AN/AZFGNZafgen0.266.566.56OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/AADXSAyala Pharmaceuticals7.18%FWPForward Pharma A/S12.57%QBIOQ BioMedN/AZFGNZafgen70.43%Insider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/AADXSAyala Pharmaceuticals0.63%FWPForward Pharma A/S71.47%QBIOQ BioMed28.20%ZFGNZafgen14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableQBIOQ BioMed3145.10 million104.18 millionNot OptionableZFGNZafgen3837.47 millionN/ANot OptionableADXS, QBIO, ZFGN, FWP, and ADDXF HeadlinesSourceHeadlineDiagnosing Diabetes: Not So Simplemedscape.com - November 2 at 7:42 AMDo New Weight Loss Meds Mean the End of Bariatric Surgery?medscape.com - October 6 at 8:53 PMPrader-Willi syndromepharmaphorum.com - August 23 at 8:34 PMThe Omnipod 5 System: Trial Results From ENDO 2021medscape.com - August 4 at 8:12 PMBeta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?medscape.com - July 5 at 5:09 PMOral Semaglutide Brings GLP-1s to Primary Caremedscape.com - May 20 at 8:49 PMClinical Trials - Different Phases of the trial News, Research and Latest Updatesmedindia.net - May 20 at 3:49 PMObesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital Journalnews.google.com - May 12 at 2:12 PMWeight Loss and Obesity Management Market Insights With ... - Taiwan Newsnews.google.com - May 11 at 3:06 AMGlobal Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern Examinernews.google.com - May 4 at 6:30 PMWeight Loss and Obesity Management Market May See a Big Move ... - Digital Journalnews.google.com - May 2 at 1:13 PMIronwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best Stocksnews.google.com - May 2 at 8:13 AMThe Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulationmedscape.com - April 29 at 8:09 PMFast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape Referencenews.google.com - April 22 at 12:41 AMAnti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital Journalnews.google.com - April 20 at 9:32 AMAnti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPRnews.google.com - April 14 at 8:21 AMNew ADA Standards: Promoting Healthmedscape.com - April 13 at 7:20 AMNew ADA Standards: Promoting Healthmedscape.com - April 13 at 7:20 AMAnti-Obesity Drugs Market Set to Register a CAGR of 16.10% and ... - GlobeNewswirenews.google.com - April 10 at 12:56 PMGlobal Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030marketwatch.com - April 9 at 10:32 AMAnti-Obesity Drugs Market is expected to rise at A CAGR Of 16.1% during the forecast period 2023 to 2031: Grow - openPRnews.google.com - April 5 at 7:34 AMAnti-Obesity Drugs Market to grow at a CAGR of over 16.1% from 2023 to 2031, reveals Growth Plus Reports - openPRnews.google.com - March 22 at 11:43 AMIndian Anti-Obesity Drug Market 2023 : Projected to Deliver Greater Revenues during the Forecast Period 2028 - openPRnews.google.com - March 1 at 1:17 PMZafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug Resultsthestreet.com - February 26 at 7:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAddex TherapeuticsOTCMKTS:ADDXFAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Ayala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Forward Pharma A/SNASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.Q BioMedOTCMKTS:QBIOQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.ZafgenNASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.